Alternative Splice Forms of VEGF in Colorectal Cancer - Possible Value in Anti-VEGF Therapy
N/A
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Colorectal Cancer
Both
Colorectal Cancer
Trial Information
Alternative Splice Forms of VEGF in Colorectal Cancer - Possible Value in Anti-VEGF Therapy
OBJECTIVES:
- Determine whether the balance of splice form expression alters susceptibility of tumors
in vivo to respond to anti-VEGF therapy.
OUTLINE: Tumor tissue samples collected on clinical trial E-3200 are analyzed for laboratory
endpoints.
Inclusion Criteria
DISEASE CHARACTERISTICS:
- Tumor tissue samples available from patients with advanced or metastatic
adenocarcinoma of the colon or rectum
- Receiving bevacizumab on clinical trial E-3200
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Type of Study:
Observational
Study Design:
N/A
Outcome Measure:
Mean scores for VEGFb and pan-VEGF gene expression by IHC
Safety Issue:
No
Principal Investigator
David Bates, PhD
Investigator Role:
Study Chair
Investigator Affiliation:
Bristol Heart Institute at University of Bristol
Authority:
United States: Federal Government
Study ID:
CDR0000560986
NCT ID:
NCT00897754
Start Date:
July 2007
Completion Date:
Related Keywords:
- Colorectal Cancer
- adenocarcinoma of the colon
- adenocarcinoma of the rectum
- recurrent rectal cancer
- stage III rectal cancer
- stage IV rectal cancer
- recurrent colon cancer
- stage III colon cancer
- stage IV colon cancer
- Colorectal Neoplasms
Name | Location |
|---|
